



TUESDAY, JANUARY 13, 2009

TOPIC: Growth Strategies in the Midst of Economic Turmoil

SPEAKERS: Viren Mehta, Ph.D., founder and managing member of Mehta Partners, LLC.

Dr. Viren Mehta provides investment and strategic advice to the pharmaceutical and biotechnology companies around the world. He notes that a biopharmaceutical company has two main ways to generate growth today: through innovation or through emerging markets. Since the innovation path to growth has become increasingly difficult, many companies are looking towards emerging markets and exploring ways to profit from the growth potential and cost savings offered by those markets and the partners in those markets.

The recently announced acquisition of Ranbaxy by Daiichi Sankyo, which Dr. Mehta himself orchestrated, is an example of just such a growth strategy. At this program, Dr. Mehta will discuss how to assess growth opportunities in emerging markets such as India and China, in the face of world economic turmoil. He will point out the advantages of such a bold initiative, paint a picture of the landscape in India and other markets after the Daiichi-Sankyo/Ranbaxy deal, and discuss the significance of this deal to other companies - Japanese companies, other generic manufacturers, others in the Indian and Emerging Markets, and Big Pharma in the West as well.

Dr. Mehta has over thirty years of experience in the pharmaceutical and biotechnology industry, investment research, strategic advisory services, and asset management. Prior to founding Mehta and Isaly, Dr. Mehta was a part of the strategic planning team of the International division at Merck & Co. Dr. Mehta earned a Doctor of Pharmacy at the University of Southern California, and an MBA from the Anderson School of Business at the University of California, Los Angeles.